Accuray Inc is primarily active in the medical technology industry.

The main competitors of Accuray Inc in the market include Varian Medical Systems, Elekta AB, and ViewRay Inc.

Accuray Inc. is a renowned medical technology company specializing in the development and sale of innovative radiation therapy solutions. Founded in 1990, Accuray is based in Sunnyvale, California. The company's flagship product, the CyberKnife System, is a non-invasive robotic radiosurgery system utilized for treating cancerous and non-cancerous tumors. With a blend of advanced robotics and real-time tumor tracking, Accuray's CyberKnife System enables precise delivery of radiation therapy, minimizing damage to surrounding healthy tissues. Over the years, Accuray has consistently introduced cutting-edge advancements in the field of radiosurgery, revolutionizing the way cancer is treated globally. Accuray's commitment to improving patient outcomes has made it a trusted name in the healthcare industry.

Accuray Inc has achieved several significant milestones in its history. One notable achievement is the development and introduction of the CyberKnife System, a robotic radiosurgery system that revolutionized cancer treatment. The company also attained regulatory clearance for its innovative TomoTherapy System, which combines precise radiation therapy with integrated CT imaging. Accuray Inc has expanded its global reach, establishing a presence in over 100 countries worldwide. Moreover, the company has consistently demonstrated a commitment to innovation, investing in research and development to enhance its advanced treatment solutions. These achievements highlight Accuray Inc's dedication to improving cancer care and solidify its position as a leader in the field.

Accuray Inc is primarily present in several countries and regions across the globe. The company has a strong presence in North America, with operations in the United States and Canada. Additionally, Accuray Inc has expanded its reach to Europe, including countries such as Germany, France, Italy, and the United Kingdom. The company is also present in the Asia-Pacific region, with a significant presence in Japan, China, India, and Australia. Accuray Inc's global presence allows it to cater to a wide range of markets and provide its innovative medical solutions to healthcare professionals worldwide.

Accuray Inc represents values of innovation, precision, and patient-centric care in the field of radiation oncology. With a corporate philosophy focused on improving the lives of cancer patients, Accuray Inc offers cutting-edge solutions like the CyberKnife and Radixact systems. These advanced technologies provide non-invasive and highly accurate treatment options, enabling personalized cancer care and improved quality of life. Accuray Inc aims to empower healthcare professionals with state-of-the-art tools, fostering collaboration and optimal treatment outcomes. As a global leader in radiation therapy, Accuray Inc continues to revolutionize cancer treatment, making a positive impact on patients worldwide.

Analysts currently set an average price target of 3,95 USD for the Accuray stock (median: 3,95 USD), implying +1 308,1 % versus the latest price. The consensus is based on 8 analyst ratings.

Accuray Analyytikkojen kursstavoitteet 2026

8 analysts currently rate the Accuray stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Accuray to generate revenue of 406,30 M USD and earnings per share of −0,35 USD.

Accuray Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Accuray share trades at 0,24 EUR (0,28 USD).

The Accuray share (ARAY) is listed on 7 stock exchanges, including: NASDAQ (ARAY), Frankfurt (XEJ.F), München (XEJ.MU), Düsseldorf (XEJ.DU), London (0H8I.L), London (0H8I.L), SIX (Zürich) (XEJ.SW).

Accuray Inc is a global manufacturer of medical devices for the radiation therapy treatment of cancer. The company's main products are the CyberKnife and TomoTherapy systems. The company also offers a range of services and support facilities for its devices. In addition, Accuray Inc also provides software solutions for medical imaging and workflow management. The CyberKnife systems by Accuray target tumor and non-tumor areas for precise treatment. This system uses robotic precision and image-guided technology to deliver radiation to the exact location where the tumor is located. This method spares healthy cells and allows for complete recovery. The CyberKnife system is used in diverse treatment areas including brain tumors, liver tumors, spine cancer, and prostate cancer. The TomoTherapy system is a computer-assisted procedure that integrates imaging and radiation planning in one system. The TomoTherapy systems combine continuous, rotating radiation source with precise imaging technology for accuracy and precision in radiation therapy. This system is used for various types of cancer including head and neck cancer, breast cancer, lung cancer, and prostate cancer. Accuray also offers software solutions for medical imaging and workflow management. The iDMS software by Accuray enables healthcare facilities to automatically manage and monitor their session bookings, orders for radiation therapy, and approved quantity. The uMI software allows for easy and effective imaging and radiation planning for the CyberKnife and TomoTherapy systems. The company also operates a clinical services division which provides a variety of management and support services including training, installation, technical support, and system maintenance. Accuray's commitment to customer satisfaction from this division is a crucial part of its business model as these services ensure the long-term safety and efficacy of the systems. Accuray sells its products to leading hospitals and medical centers in the USA, Europe, Asia, and other parts of the world. The company targets customers with a high need for precise radiation therapy, including oncologists, radiation therapists, and other medical professionals. Accuray's business model creates value by providing innovative and effective cancer treatment devices and software solutions. The company also has a high appreciation in the clinical division, which ensures the long-term health of customers. The demand for precise radiation therapy will continue to grow as the cancer rate in the population increases. This makes Accuray's business model sustainable and will continue to expand in the future.

odotettu liikevaihto Accuray on 406,30 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Accuray on −42,13 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Accuray:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,80. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Accuray-osakkeen arvostusta.

Accuray:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,08. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Accuray-osakkeen arvostuskennuslukuna.

Accuray:n Eulpool-laatuscore on 2/10.

Accuray:n ISIN on US0043971052. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Accuray:n WKN on A0MKWM. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Accuray:n ticker on ARAY. Tämä pörssinoteeraus käytetään Accuray-osakkeiden kauppaan pörssissä.

Accuray maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Accuray kuuluu sektoriin 'Terveydenhuolto'.

Accuray:n osingot jaetaan valuutassa USD.